Related Experiment Video
Updated: Dec 24, 2025
06:32
Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring
Published on: July 14, 2023
1.7K
DBS Programming: An Evolving Approach for Patients with Parkinson's Disease
Aparna Wagle Shukla1, Pam Zeilman1, Hubert Fernandez2
1Center for Movement Disorders and Neurorestoration, Department of Neurology, University of Florida, Gainesville, FL, USA.
Parkinson'S Disease
|November 18, 2017
Summary
Deep brain stimulation (DBS) programming is crucial for Parkinson's disease treatment. Advances in programming techniques and computer-guided systems aim to improve symptom control and patient access to care.
Area of Science:
- Neurosurgery
- Neurology
- Biomedical Engineering
Background:
- Deep brain stimulation (DBS) is a key therapy for Parkinson's disease motor symptoms.
- Effective DBS requires precise lead placement and efficient programming for optimal clinical outcomes.
- Current DBS programming is manual, time-consuming, and lacks standardized protocols.
Purpose of the Study:
- To review current practices in DBS programming.
- To discuss recent technological advancements in DBS programming.
- To explore future directions in DBS programming for improved efficiency and patient access.
Main Methods:
- Review of current DBS programming guidelines and procedures.
- Analysis of recent technological innovations in DBS pulse delivery (interleaving, fractionated current, directional steering).
- Discussion of emerging computer-guided and remote programming solutions.
Main Results:
- Technological improvements focus on enhancing symptom control and minimizing side effects.
- Novel DBS pulses and current steering offer more precise neuromodulation.
- Computer-guided and remote programming show potential to increase efficiency and accessibility.
Conclusions:
- Optimizing DBS programming is essential for successful Parkinson's disease management.
- Emerging technologies promise more effective and personalized DBS therapy.
- Future programming strategies may enhance clinical workflow and broaden patient access to DBS care.
Related Concept Videos
01:24Parkinson's Disease: Treatment
862
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
862
01:15Parkinson's Disease: Overview
1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
01:37Neural Regulation
42.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.9K
01:21EPS and iPS Cells in Disease Research
3.2K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.2K
01:22Alzheimer's Disease: Treatment
691
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
691